CSL Ltd
Company Profile
Business description
CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world’s second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
Contact
655 Elizabeth Street
MelbourneVIC3000
AUST: +61 393891911
E: InvestorRelations@csl.com.au
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
32,000
Stocks News & Analysis
stocks
The ASX's most shorted stocks
stocks
Should you snap up shares in this volatile ASX player?
stocks
Have these dogs of the ASX fallen too far?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,443.70 | 35.30 | -0.42% |
| CAC 40 | 7,525.57 | 50.45 | -0.67% |
| DAX 40 | 19,074.74 | 29.36 | -0.15% |
| Dow JONES (US) | 41,954.24 | 398.51 | -0.94% |
| FTSE 100 | 8,207.87 | 95.75 | -1.15% |
| HKSE | 20,926.79 | 2,172.99 | -9.41% |
| NASDAQ | 17,923.90 | 213.95 | -1.18% |
| Nikkei 225 | 38,937.54 | 395.20 | -1.00% |
| NZX 50 Index | 12,555.99 | 40.88 | -0.32% |
| S&P 500 | 5,695.94 | 55.13 | -0.96% |
| S&P/ASX 200 | 8,176.90 | 28.50 | -0.35% |
| SSE Composite Index | 3,489.78 | 153.28 | 4.59% |